- Home
- AUTL vs PROK Comparison
AUTL vs PROK Comparison
Compare AUTL & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUTL
- PROK
- Stock Information
- Founded
- AUTL 2014
- PROK 2015
- Country
- AUTL United Kingdom
- PROK United States
- Employees
- AUTL N/A
- PROK N/A
- Industry
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AUTL Health Care
- PROK Health Care
- Exchange
- AUTL Nasdaq
- PROK Nasdaq
- Market Cap
- AUTL 368.6M
- PROK 417.1M
- IPO Year
- AUTL 2018
- PROK N/A
- Fundamental
- Price
- AUTL $1.37
- PROK $2.43
- Analyst Decision
- AUTL Strong Buy
- PROK Strong Buy
- Analyst Count
- AUTL 5
- PROK 4
- Target Price
- AUTL $9.12
- PROK $6.25
- AVG Volume (30 Days)
- AUTL 2.4M
- PROK 1.7M
- Earning Date
- AUTL 11-12-2025
- PROK 11-10-2025
- Dividend Yield
- AUTL N/A
- PROK N/A
- EPS Growth
- AUTL N/A
- PROK N/A
- EPS
- AUTL N/A
- PROK N/A
- Revenue
- AUTL $51,128,000.00
- PROK $744,000.00
- Revenue This Year
- AUTL $643.50
- PROK $471.74
- Revenue Next Year
- AUTL $108.69
- PROK N/A
- P/E Ratio
- AUTL N/A
- PROK N/A
- Revenue Growth
- AUTL 406.67
- PROK N/A
- 52 Week Low
- AUTL $1.11
- PROK $0.46
- 52 Week High
- AUTL $3.45
- PROK $7.13
- Technical
- Relative Strength Index (RSI)
- AUTL 44.06
- PROK 37.96
- Support Level
- AUTL $1.23
- PROK $2.56
- Resistance Level
- AUTL $1.52
- PROK $2.88
- Average True Range (ATR)
- AUTL 0.11
- PROK 0.25
- MACD
- AUTL -0.01
- PROK -0.08
- Stochastic Oscillator
- AUTL 31.76
- PROK 19.34
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.